Aetna secures more than 81% of Medicare Advantage members in 4-Star plans and over 63% in 4.5-Star plans for 2026.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 09 2025
0mins
Source: Newsfilter
Aetna's Medicare Advantage Success: Aetna announced that over 81% of its Medicare Advantage members are enrolled in plans rated 4 stars or higher for 2026, with more than 63% in 4.5-star plans, reflecting the company's commitment to quality care.
Consistent High Ratings: Several of Aetna's major contracts have achieved high ratings, including a 4.5-star rating for 14 consecutive years for its H5522 contract, demonstrating Aetna's leadership in providing quality Medicare solutions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVS
Wall Street analysts forecast CVS stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 93.320
Low
91.00
Averages
96.71
High
105.00
Current: 93.320
Low
91.00
Averages
96.71
High
105.00
About CVS
CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. The Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and, through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Housing Investment Scale: CVS Health's $9 million investment through R4 Capital, in collaboration with Diocesan Housing Services Corporation and The Walters Group, supports the development of a 75-unit affordable housing project for seniors in Williamstown, New Jersey, reflecting the company's long-standing commitment to improving community health.
- Diverse Funding Sources: The project secured $8 million in HUD funding, $14 million in NJHMFA construction financing, and $7 million from the Affordable Housing Production Fund, highlighting the importance of multi-party collaboration in addressing the housing needs of older adults.
- Addressing Housing Burden: With 60% of New Jersey renters aged 65 and older facing housing cost burdens, CVS Health's investment not only meets the urgent need for affordable housing but also helps residents live safely and independently by providing personalized medical and social services.
- Significant Economic Impact: CVS Health's operations in New Jersey are projected to generate an estimated $12.5 billion economic impact in 2024, supporting over 39,000 jobs while contributing approximately $882.1 billion in state and local taxes, further solidifying its vital role in the community.
See More
- Legal Challenge: On May 22, CVS filed a lawsuit in Nashville to block Tennessee's new law that would force the closure of its 136 pharmacies in the state, impacting over 2,000 employees and 1.5 million patients' access to medications.
- Legislative Background: The law, signed by Governor Bill Lee, prohibits companies from owning both pharmacies and pharmacy benefit managers (PBMs), taking effect on July 1, 2028; CVS claims this law undermines patient interests and restricts fair competition.
- Industry Impact: CVS spokesperson stated that the law would increase prescription drug costs and would not lower costs for anyone, highlighting the growing regulatory scrutiny on large healthcare corporations amid congressional and state-level focus on drug pricing.
- Lawsuit Objectives: CVS's lawsuit seeks a federal judge's ruling that the law violates federal statutes and aims to prevent Tennessee from implementing it, naming the Tennessee Board of Pharmacy and other officials as defendants, demonstrating CVS's strong opposition and commitment to protecting patient rights.
See More
- Significant Investment Returns: Since May 2024, CVS Health shares have generated an 80% total return, reflecting the company's positive progress in cultural and operational turnaround, indicating an increase in long-term investment value.
- Strategic Holdings Adjustment: Glenview rebalanced its holdings in May 2025 and 2026, reducing CVS shares by 3.75 million to align with the fund's diversification parameters while creating capital for further investment opportunities in a volatile macro environment.
- Ongoing Confidence: Despite the adjustments, CVS Health remains one of Glenview's top three holdings, with management expressing strong confidence in CVS's near, medium, and long-term outlook, highlighting its stability and potential in the market.
- Enhanced Operational Efficiency: CVS Health has improved drug reimbursement processes and expedited medical claims handling through increased operational intensity and transparency, positively impacting the health and well-being of the majority of Americans, showcasing its innovative leadership in the industry.
See More
- Earnings Surprise: CVS reported a 6.2% year-over-year revenue increase to $100.4 billion in Q1, exceeding analyst expectations of $94.4 billion, with EPS at $2.30, a 62% rise, prompting the company to raise its full-year guidance, now forecasting EPS between $6.24 and $6.44 and operational cash flow of at least $9.5 billion, indicating robust financial health.
- Attractive Dividend Yield: With a current dividend yield of approximately 2.8%, more than double the S&P 500 average, CVS's consistent free cash flow, ranging from $9 billion to $10.5 billion in recent years, supports its dividend payments, enhancing investor confidence.
- Insurance Segment Recovery: CVS's health insurance unit Aetna saw a 3.3% revenue increase to $35.9 billion, with improved margins due to reduced medical utilization costs, as the medical benefit ratio dropped from 87.3% to 84.6%, reflecting strategic adjustments to enhance insurance profitability.
- Debt Concerns Persist: While CVS shows signs of improving profitability, its long-term debt of $86.4 billion remains a drag on performance, with a capital-intensive acquisition strategy leading to significant interest expenses, although total debt has decreased by 1.5% year-over-year to $175 billion, warranting attention on its impact on expansion and stock buybacks.
See More
- Significant Revenue Growth: CVS reported a 6.2% year-over-year revenue increase to $100.4 billion in Q1, surpassing analyst expectations of $94.4 billion, with EPS at $2.30, reflecting a 62% increase, indicating a strong rebound in its healthcare and pharmacy segments.
- Upgraded Full-Year Guidance: The company raised its full-year EPS forecast to between $6.24 and $6.44, and operational cash flow expectations increased from $9 billion to at least $9.5 billion, showcasing management's confidence in improving market demand and performance.
- Healthcare Segment Recovery: Revenue from the Aetna health insurance unit rose 3.3% year-over-year to $35.9 billion, with a significant drop in the medical benefit ratio to 84.6%, demonstrating effective cost control and profit enhancement strategies.
- Debt Management Challenges: Despite CVS's long-term debt standing at $86.4 billion, it is gradually reducing total debt by 1.5%, indicating efforts to improve financial health under a capital-intensive acquisition strategy, allowing for future expansion and stock buybacks.
See More
- Comprehensive Support for Military Families: CVS Health is committed to supporting service members, veterans, and their families through partnerships with nonprofits, providing healthcare access, community solutions, and economic opportunities, ensuring they receive necessary support and resources throughout their service lifecycle.
- Innovative Community Solutions: In North Carolina, CVS Health has launched MFAN's Pantry Restock Program and community support initiatives with Hope For The Warriors, with plans to expand to additional states this year, addressing the real challenges military families face during transitions and enhancing their quality of life.
- Economic Stability and Entrepreneurship Support: In 2025, CVS Health spent $292 million with veteran-owned small businesses, supporting career development and entrepreneurship for veterans and their spouses, helping them gain training and certification within the company's supply chain to promote economic mobility.
- Enhancing Community Connections: CVS Health collaborates with organizations like the Travis Manion Foundation to invest in programs that help veterans and military spouses continue serving their communities, emphasizing the importance of purpose for health and fostering physical wellness and social connections.
See More











